美国成人流感、COVID-19 和呼吸道合胞病毒疫苗接种覆盖率——2024 年秋季
研究利用国家免疫调查-成人 COVID 模块电话调查数据,监测美国≥18 岁成人 2024-25 呼吸道病毒季节流感、COVID-19 和 RSV 疫苗接种覆盖率。截至 2024 年 11 月 9 日,34.7% 成人接种流感疫苗,17.9% 接种 COVID-19 疫苗;≥75 岁成人 39.7%、60-74 岁重症 RSV 高风险成人 31.6% 曾接种 RSV 疫苗。覆盖率因辖区和人口学特征而异,年轻成人和无医保者最低;约 35% 和 41% 成人对流感、COVID-19 疫苗表示确定或可能接种或不确定,40% ≥75 岁成人对 RSV 疫苗持类似态度。
要点
- 截至 2024 年 11 月 9 日,34.7% 成人接种流感疫苗,17.9% 接种 COVID-19 疫苗。
- ≥75 岁成人 RSV 疫苗曾接种率 39.7%,60-74 岁重症高风险成人 31.6%。
- 覆盖率在年轻成人和无医保者中最低;约 35%-41% 成人对接种持开放或不确定态度。
核心结论
- 早期季节估计显示许多成人未受呼吸道病毒保护,但许多人对接种持开放态度,卫生保健提供者和免疫规划仍有时间扩大外展和促进接种以提高覆盖率。
研究设计与样本
- 使用国家免疫调查-成人 COVID 模块(随机数字拨号手机调查)数据,监测美国≥18 岁成人流感、COVID-19 和 RSV 疫苗接种覆盖率。
主要发现
- 截至 2024 年 11 月 9 日,估计 34.7% 的≥18 岁成人报告接种 2024-25 呼吸道病毒季节流感疫苗,17.9% 报告接种 COVID-19 疫苗。
- 39.7% 的≥75 岁成人曾接种 RSV 疫苗,31.6% 的 60-74 岁重症 RSV 高风险成人曾接种 RSV 疫苗。
- 覆盖率因辖区和人口学特征而异,在年轻成人和无医保者中最低。
- 约 35% 的≥18 岁成人报告确定或可能将接种流感疫苗或不确定,约 41% 对 COVID-19 疫苗持类似态度;40% 的≥75 岁成人对 RSV 疫苗持类似态度。
关键数值与推荐
- ACIP 推荐所有≥6 月龄者(包括≥18 岁成人)每年接种流感疫苗和 COVID-19 疫苗。
- ACIP 推荐≥75 岁成人以及 60-74 岁重症 RSV 疾病风险增加者接种单剂次终身 RSV 疫苗。
临床怎么用
- 卫生保健提供者和免疫规划仍有时间扩大外展活动并促进接种,以提高覆盖率、准备应对呼吸道病毒季节高峰。
- 使用这些数据可帮助卫生保健提供者和免疫规划识别接种不足人群并了解接种模式,以指导疫苗接种活动的规划、实施和评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Advisory Committee on Immunization Practices (ACIP) recommends annual influenza and COVID-19 vaccination for all persons aged ≥6 months, including adults aged ≥18 years. ACIP also recommends a single lifetime dose of respiratory syncytial virus (RSV) vaccine for adults aged ≥75 years and for those aged 60-74 years who are at increased risk for severe RSV disease. Data from the National Immunization Survey-Adult COVID Module, a random-digit-dialed cellular telephone survey of U.S. adults aged ≥18 years, are used to monitor influenza, COVID-19, and RSV vaccination coverage. By the week ending November 9, 2024, an estimated 34.7% of adults aged ≥18 years reported having received an influenza vaccine, and 17.9% reported having received a COVID-19 vaccine for the 2024-25 respiratory virus season; 39.7% of adults aged ≥75 years, and 31.6% of adults aged 60-74 years at increased risk for severe RSV, had ever received an RSV vaccine. Coverage varied by jurisdiction and demographic characteristics and was lowest among younger adults and those without health insurance. Although early season estimates indicate that many adults are unprotected from respiratory virus infections, many appeared open to vaccination: overall, approximately 35% and 41% of adults aged ≥18 years reported that they definitely or probably will receive or were unsure about receiving influenza and COVID-19 vaccines, respectively, and 40% of adults aged ≥75 years reported that they definitely or probably will receive or were unsure about receiving RSV vaccine. Health care providers and immunization programs still have time to expand outreach activities and promote vaccination to increase coverage in preparation for the height of the respiratory virus season. Using these data can help health care providers and immunization programs identify undervaccinated populations and understand vaccination patterns to guide planning, implementation, and evaluation of vaccination activities.
引用
- Kriss JL, Black CL, Razzaghi H, et al. Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2024. MMWR Morb Mortal Wkly Rep. 2024. PMID: 39570786. doi:10.15585/mmwr.mm7346a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。